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Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis.
A 1H-MRS Study
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Health, Parkville, Australia; 5Brain Research Institute, Heidelberg, Australia; 6Queensland University of Technology, Brisbane, Australia
Ethyl-eicosapentaenoic acid (E-EPA) is an omega-3 fatty acid that has been used in a range of neuropsychiatric conditions with some
benefits. However, its mechanism of action is unknown. Here, we investigate its effects on in vivo brain metabolism in first-episode
psychosis (FEP). Proton magnetic resonance spectroscopy at 3 T was performed in the temporal lobes of 24 FEP patients before and
after 12 weeks in the context of a larger double-blind, placebo-controlled E-EPA augmentation study. Treatment group effects for
glutathione (F1,12¼ 6.1, p¼ 0.03), and a hemisphere-by-group interaction for glutamine/glutamate (F1,20¼ 4.4, p¼ 0.049) were found.
Glutathione increased bilaterally and glutamate/glutamine increased in the left hemisphere following E-EPA administration. Improvement
in negative symptoms correlated with metabolic brain changes, particularly glutathione (r¼0.57). These results suggest that E-EPA
augmentation alters glutathione availability and modulates the glutamine/glutamate cycle in early psychosis, with some of the metabolic
brain changes being correlated with negative symptom improvement. Larger confirmatory studies of these postulated metabolic brain
effects of E-EPA are warranted.
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INTRODUCTION
Omega-3 fatty acids are essential for normal brain
development, synaptic plasticity, and function (Bazan,
2005; Bazan et al, 1997). Cell biological and molecular
studies suggest that omega-3 fatty acids modulate mem-
brane fluidity (Hashimoto et al, 1999), dopaminergic
(Piomelli, 1994) and serotonergic (Yao et al, 2004)
neurotransmission, and differentially alter gene expression
(Kitajka et al, 2002; Salvati et al, 2004). Furthermore,
preclinical studies suggest that omega-3 fatty acids have
neuroprotective properties (Lonergan et al, 2002; Lynch
et al, 2006; Martin et al, 2002). Animal and human studies
provide ample evidence that essential fatty acid deprivation
during pregnancy is associated with developmental and
behavioral abnormalities (Innis et al, 1999; Wainwright
et al, 1994a, b Q1) that are ameliorated by essential fatty acid
supplementation (Helland et al, 2003; Wainwright et al,
1994a, b).
Decreased omega-3 fatty acids levels have been found in
blood and postmortem brain cell membranes in several
neuropsychiatric conditions (Schachter et al, 2005), in
particular schizophrenia (Berger et al, 2006; Fenton et al,
2000; McNamara et al, 2007), bipolar affective disorders
(Chiu et al, 2003; Hitzemann et al, 1984; Mahadik et al,
1996; Ranjekar et al, 2003), major depression (Frasure-
Smith et al, 2004; McNamara et al, 2006; Mischoulon and
Fava, 2000; Peet et al, 1998), and attention deficit
(hyperactivity) disorder (Burgess et al, 2000; Stevens et al,
1995).
Controlled clinical trials in established schizophrenia
indicate that either sole or augmentation therapy with
omega-3 fatty acids may be beneficial (Emsley et al, 2002;
Joy et al, 2003; Mellor et al, 1996; Peet et al, 2001), with
some conflicting results (Emsley et al, 2006; Fenton et al,
2001; Peet and Horrobin, 2002a, b Q2). Furthermore, controlled
clinical trials in treatment-resistant depression (Nemets
et al, 2002; Peet and Horrobin, 2002a, b), bipolar depression
(Keck et al, 2006), bipolar affective disorder (Stoll et al,
1999), borderline personality disorder (Zanarini and
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Frankenburg, 2003), incarcerated young males (Gesch et al,
2002), and children with developmental coordination
disorders (Richardson and Montgomery, 2005) also suggest
that omega-3 fatty acids may modulate mood, impulsivity,
and aggression, while potential neuroprotective effects were
found in Huntington’s disease (Puri et al, 2002, 2005). A
recently presented, yet unpublished, study (Amminger et al,
2007) suggests that omega-3 fatty acids may delay the onset
of frank psychosis in adolescents at ultra-high risk of
psychotic disorders.
The underlying in vivo mechanisms of action of omega-3
fatty acids are still speculative. A recent study investigating
the in vivo brain effects of omega-3 fatty acids using T2
relaxation time in patients with bipolar affective disorder
supports preclinical findings that omega-3 fatty acids
modulate membrane integrity (Hirashima et al, 2004),
thereby potentially altering signal transduction and receptor
binding (Vereb et al, 2003). One way to further investigate
the potential in vivo brain effects of omega-3 fatty acids is in
vivo proton magnetic resonance spectroscopy (1H-MRS),
which can estimate regional concentrations of various brain
metabolites. For example, alterations in N-acetylaspartate
(NAA) most likely reflect changes in neuronal integrity,
changes in glutamate/glutamine (GLX) may be linked to
excitotoxicity, and changes in glutathione (GSH) related to
oxidative stress (Nakamura et al, 1997) and/or apoptotic
activity (Dringen, 2000). GSH synthesis is mainly regulated
in astrocytes, and is important as a defense mechanism
against excess NO, while functioning to protect glial and
neuronal mitochondria (Gegg et al, 2003, 2005).
1H-MRS studies in established schizophrenia found
altered metabolite profiles (Abbott and Bustillo, 2006;
Bertolino and Weinberger, 1999; Keshavan et al, 2000; Lyoo
and Renshaw, 2002; Stanley, 2002). However, 1H-MRS
studies of first-episode psychosis (FEP) are less conclusive
(Renshaw et al, 1995). The stage of disease at which
metabolite abnormalities are established is unclear; how-
ever, studies in young, untreated FEP patients suggests that
the neuronal integrity is largely preserved before onset of
psychosis (Wood et al, 2003), while the majority of 1H-MRS
studies in chronic schizophrenia show reduced levels of
NAA.
Here, we present a study investigating the metabolic in
vivo brain effects of ethyl-eicosapentaenoic acid (E-EPA)
using this technique in drug-naı¨ve or early treated FEP. We
speculated that E-EPA would show neuroprotective proper-
ties in vivo by maintaining neuronal integrity, protecting
the brain against excitotoxicity, and support antioxidative
defense. We chose E-EPA because previous controlled
studies in schizophrenia have shown some benefits (Emsley
et al, 2002, 2006; Horrobin et al, 2002; Peet, 2003, 2001; Peet
and Horrobin, 2002a, b), and because treatment response
has been associated with an increase in EPA (Arvindakshan
et al, 2003).
PATIENTS AND METHODS
Patients
All study participants had to be patients of the Early
Psychosis Prevention & Intervention Centre (EPPIC),
Melbourne, Australia that covers a service area with an
approximate population of 880 000. Study inclusion criteria
were (1) age between 15 to 29 years (inclusive) and (2)
currently psychotic as reflected by the presence of at least
one psychotic symptom daily for more than 1 week (either
delusions, hallucinations, disorder of thinking, and/or
speech other than simple acceleration or retardation, and
disorganized bizarre, or markedly inappropriate behavior).
Psychotic diagnoses were confirmed using the semi-
structured DSM-IV interview for research (First et al,
2002). Exclusion criteria were cases of drug-induced
psychosis (self-limiting drug-related psychotic experiences
that resolved within less than 7 days of drug abstinence),
first episode mania, organic disorders presenting with
psychotic symptoms (eg, temporal lobe epilepsy, significant
neurological conditions), history of intellectual disability, or
history of head injury with loss of consciousness.
Participants of this study were part of a larger rando-
mized double-blind placebo-controlled clinical trial (Berger
et al, 2007) investigating the augmenting effects of E-EPA
((5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoic acid)
in 80 drug-naı¨ve or early-treated FEP patients who
completed repeated MRI/MRS scans. Twenty-four patients
agreed to perform 1H-MRS assessments before commence-
ment of the study medication and after 12 weeks. Twelve in
each group either received 2 g oral E-EPA or 2 g placebo oil,
taken as separate 1-g doses in the morning and evening
(see Table 1 for details). All participants received atypical
antipsychotic medication (taken nightly) according to the
guidelines of the Early Psychosis Prevention & Intervention
Centre, Melbourne, Australia (McGorry and Warner, 2002).
Full details of the larger clinical trial design, patient
characteristics, and the clinical outcome measures can be
NPG_NPP_1301628
Table 1 Demographic Details for the Two Treatment Groups
E-EPA
group
Placebo
group
Age (years)a 19.6±2.9 21.4±4.1
Proportion male 67% 100%
Proportion schizophrenia,
schizophreniform psychosis
58% 83%
Proportion smokers at baselineb 36% 55%
Proportion antipsychotic-naı¨ve at baseline 42% 58%
Time between scans (days)a 86.2±6.8 83.2±3.9
Proportion receiving risperidone/
quetiapine/olanzapine
6/4/2 4/3/5
Number of days on antipsychotic
medication at baselinec
1 (0–16) 0 (0–11)
Total antipsychotic dose between scans
(mg of CPZ equivalent)a
15634±8264
19241±6976
GAF at baselinea 43.7±13.1 44.7±8.9
PANSS total at baselinea 81.5±14.3 82.2±17.6
Duration of untreated psychosis (months)c 3 (0.25–7) 5 (0.25–36)
aData presented as mean and standard deviation.
bData unavailable for two participants (one in each group).
cData presented as median and range.
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found elsewhere (Berger et al, 2007). The local research and
ethics committee approved this protocol and each subject
(or their guardian) provided written informed consent.
Proton Magnetic Resonance Spectroscopy
Short-echo (TE 30 ms) acquisition proton MRS was
performed on a 3 T GE LX Horizon scanner (GE Healthcare,
Milwaukee) using a PRESS sequence with two chemical-
shift-selective imaging pulses for water suppression. Spectra
were acquired with 128 transients of 2 k data points over a
frequency width of 5000 Hz with TR¼ 3 s. Spectra were
recorded from single isotropic 2-cm voxels placed in each
temporal lobe. Three-plane localizing images were acquired
to allow prescription of regions of interest (ROI) for spectra.
Sagittal plane, 2-cm thick scout images (T1 spin echo),
followed by 2-cm thick coronal images, centered in the
plane of the ponto-medullary junction, were acquired. An
ROI in each temporal lobe was selected in the coronal plane,
with the lateral aspect of the hippocampus in the center of
the ROI. The sagittal image was viewed to ensure that the
ROI did not include petrous temporal bone. This region of
interest consisted largely of the anterior hippocampus
(450%). Spectra were analyzed with LCModel (Provencher,
1993), using a basis set of 15 metabolites acquired on-site,
incorporating the standard macromolecule and baseline
fitting routines of LCModel. Metabolite concentrations were
estimated following calibration using the tissue water signal
as an internal standard. Results are presented in institu-
tional units approximating millimolar concentration, and
were rejected if the Cramer–RaoQ3 lower bound was greater
than 30%. Full-width-half-maxima and signal-to-noise
ratios averaged 0.093±0.015 and 11.3±1.9, respectively,
across both time points and both hemispheres. Only the
following metabolites were reliably estimated in sufficient
participants at both time points to allow analysis: NAA
(includingQ4 N-acetylaspartylglutamate, NAA; n¼ 24), tri-
methylamines (TMA; n¼ 24), creatine/phosphocreatine
(Cr/PCr; n¼ 24), myo-inositol (mI; n¼ 24), glutamate/
glutamine (GLX; n¼ 23), and glutathione (GSH; n¼ 15).
Metabolite concentrations were corrected for CSF and gray
matter fraction within each voxel using SPM analysis of
segmented T1 images.
Analysis
Change scores were calculated as a percentage of the
baseline metabolite concentration for each metabolite for
each voxel. Repeated-measures ANCOVA (with hemisphere
as the repeated measure) covarying for age was performed
for each metabolite to compare differences in change
between the two treatment groups. One-sample t-tests were
used on the total group (collapsed across treatment) to test
whether the mean change in each metabolite significantly
differed from 0.
Partial correlations (controlling for age) were performed
between the change scores and change in clinical variables
regardless of treatment group.
RESULTS
The two treatment groups did not differ on baseline
metabolite levels (all p40.1) except for Cr/PCr
(F1,19¼ 8.2, p¼ 0.01), where the placebo group had
significantly higher concentrations than the EPA group.
No difference in percentage change between the two
treatment groups was identified for TMA (F1,21¼ 1.7,
p¼ 0.212), Cr/PCr (F1,21¼ 2.7, p¼ 0.115), mI (F1,21¼ 2.5,
p¼ 0.128), or NAA (F1,21¼ 0.0, p¼ 0.952). However, a
significant treatment group effect was found for GSH
(F1,12¼ 6.1, p¼ 0.03) and a significant hemisphere-by-
group interaction for GLX (F1,20¼ 4.4, p¼ 0.049). Inspec-
tion of the data (see Table 2) demonstrated that whereas the
E-EPA group showed a bilateral increase in GSH, the
increase in GLX was limited to the left hemisphere. When
the patients with affective psychotic disorders were
excluded and the analyses repeated, the effects were very
similar although not quite reaching significance.
Symptom scores generally showed an improvement,
ranging from a median improvement on the GAF scale of
14.5 points to a median change of 0 on the SAS. The change
in the PANSS negative symptom subscale significantly
correlated with three metabolites, GSH (r¼0.57,
p¼ 0.041), TMA (r¼0.48, p¼ 0.025), and Cr/PCr (r¼
0.46, p¼ 0.032), indicating that the reduction of negative
symptoms correlated strongly with percentage increase in
these metabolites (see Figure 1). No other significant
correlations (controlling for age) between percentage
metabolite change (collapsed across hemisphere) and
PANSS total, positive and general subscale scores, or CGI
and GAF were identified, although the largest correlations
for these latter two variables were with GSH (r¼ 0.28 and
r¼0.24 respectively). Furthermore, there were no correla-
tions between percentage metabolite change and cumulative
antipsychotic dose.
Correlations between percentage change for GSH and
glutamate/glutamine were positive (r¼ 0.64, p¼ 0.01),
indicating that the changes in both metabolites were closely
linked (see Figure 2). One-sample t-tests showed no
significant change in any metabolite when the two groups
were combined, although the increase in NAA approached
significance (t23¼ 1.9, p¼ 0.064; see Table 2), indicating
NPG_NPP_1301628
Table 2 Effects of 12-Week E-EPA Treatment in FEP
TMA Cr/PCr NAA mI GLX GSH
E-EPA
Left 9.8
(15.7)
16.3
(14.9)
3.3
(11.5)
14.4
(18.6)
22.0
(19.2)
45.1
(39.3)
Right 17.7
(19.1)
6.2
(13.2)
13.8
(18.2)
21.9
(24.2)
1.5
(12.7)
30.3
(24.0)
Placebo
Left 3.0
(15.7)
2.2
(14.9)
12.6
(11.5)
2.4
(18.6)
9.1
(19.2)
7.5
(39.3)
Right 0.7
(19.1)
3.9
(13.2)
3.5
(18.2)
0.8
(24.2)
2.7
(12.7)
20.7
(24.0)
Mean percentage change (95% CI) for each metabolite from each voxel.
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that NAA may have increased between baseline and follow-
up scan. Correlations between age and percent change were
positive for all metabolites, ranging from r¼ 0.46
(p¼ 0.024) for NAA to r¼ 0.33 (p¼ 0.122) for GLX,
indicating that younger age was associated with bigger
metabolic changes then in older participants (see Figure 2).
DISCUSSION
This study demonstrates metabolic in vivo brain effects of
2 g E-EPA on GSH and GLX in FEP, in which there was a
significant increase in these metabolites in subjects receiv-
ing E-EPA augmentation treatment compared with those on
treatment as usual. Further, we demonstrated that negative
symptom improvement was correlated with increases in
GSH, TMA, and Cr/PCr, and were not related to cumulative
dose of antipsychotic medication. The moderate to strong
correlation of negative symptom improvement with meta-
bolic brain changes suggests that the E-EPA-associated
increase in GSH may partially be responsible for its clinical
benefits. Our findings are of particular interest in light of
previous findings that glutathione levels are reduced (by
27%) in the cerebrospinal fluid of medication-free schizo-
phrenia patients (Do et al, 2000), and postmortem brain
tissue of patients with schizophrenia (Yao et al, 2006).
Glutathione protects dopaminergic neurons from oxidative
and excitatory damage (Grima et al, 2003; Nakamura et al,
1997). Taken together, these findings indicate that while
altered GSH metabolism might play a role in schizophrenia
and related disorders, augmentation therapy with E-EPA
may be able to normalize this and protect dopaminergic
neurons. One can speculate that the large effects of the
recently presented (not yet published) omega-3 fatty acid
supplementation study in prodromal adolescents (Ammin-
ger et al, 2007) may partially be explained by such a
neuroprotective mechanism that may be sufficient to
protect dopaminergic neurons in individuals at incipient
risk for psychotic disorders.
Interestingly, the changes in GSH and GLX were
positively correlated (r¼ 0.64, p¼ 0.01), indicating that
the metabolic changes of these two metabolites were tightly
coupled. This would be expected for metabolites involved in
the same metabolic pathway (Dringen and Hirrlinger, 2003)
when neither is at limiting concentrations for subsequent
metabolic processes. Another potential explanation for the
linked change in 1H-MRS signals may be that the changes
occur at the site of production of both metabolites.
Glutathione is mainly produced by the reaction of glutamate
with cysteine and glycine, a process occurring predomi-
nantly in astrocytes (Dringen and Hirrlinger, 2003).
Astrocytes are also responsible for the conversion of
glutamate into glutamine (Hertz, 2004; Hertz and Zielke,
2004). Astrocytes constitute nearly half of the cells in our
brain, and play a crucial role in synapse formation and
functioning (Ullian et al, 2004, 2001). A relatively minor
change in glial cell number (eg, via antiapoptotic mechan-
isms) and/or glial metabolic activity could therefore explain
our findings (Berger et al, 2003; Jarskog, 2006).
The NAA increase of the combined group between
baseline and follow-up scan, although only a trend, was
not expected. Normally, the progression of schizophrenia is
associated with a decrease in NAA (excessive loss compared
with the decrease associated with normal aging) and it has
been postulated that in particular the onset of schizophrenia
is associated with excessive synaptic pruning (Feinberg,
1982; Keshavan et al, 1994). However, our findings are
much more suggestive that the neuronal integrity was
maintained or even improved in the recovery phase of our
treated FEP sample. The latter is in line with a recent study
suggesting that atypical antipsychotic medication may
protect the brain of first-episode schizophrenia patients
from gray matter loss (Lieberman et al, 2005). The positive
correlation between age and change of in vivo brain
metabolites may indicate an advantage for younger FEP
patients with neuroprotective treatment strategies, indicat-
ing that the potential for a restoration of synaptic integrity
may decrease with adulthood (Nakamura et al, 1999;
Savvateeva et al, 2000). While this would have particular
importance for early intervention strategies of psychotic
disorders, it needs to be confirmed by additional clinical
trials.
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Figure 2 Scatterplot of the relationship between change in NAA and
age at scan for both treatment groups.
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Figure 1 Scatterplot of the relationship between change in glutathione
(GSH) and change in the PANSS negative syndrome score for both
treatment groups.
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This study has several potential limitations. First, the
sample size, although similar to previous studies (Steen
et al, 2005), is still relatively small, and we were not in the
position to match the groups on diagnosis because the
current study was embedded in a larger double-blind,
placebo-controlled study of 2 g EPA augmentation in 80
drug-naı¨ve or early treated FEP patients, limiting any
stratification procedures without breaking the blindness.
The results of our own larger clinical study suggest that E-
EPA has more impact on non-affective psychotic disorders,
accelerates treatment response, and reduces the amount of
prescribed antipsychotic (Oz et al, 2006) medication, as well
as results in better tolerability (Berger et al, 2007). It is
therefore noteworthy that the placebo group of the
embedded Magnetic Resonance Spectroscopy study had a
higher proportion of non-affective psychosis patients than
the E-EPA group, meaning that we are likely to be
underestimating the metabolic effect of E-EPA in the
current study (as E-EPA seems to be beneficial mainly in
non-affective psychosis). Second, the restriction of our ROI
to the medial temporal lobes means that we cannot
determine whether E-EPA has an effect throughout the
brain or only in the temporal lobe. Third, the lack of a
longitudinal healthy control arm means that we cannot
address the question of whether the E-EPA effects were
specific to early psychosis or a more general ‘healthy’ brain
response (Yehuda et al, 1999). Fourth, MRS measures show
normal physiological variation of between 5 and 28%
(Wellard et al, 2005), meaning that it is potentially possible
that our findings are merely due to normal fluctuations in
metabolites. However, it seems unlikely that we would have
found treatment group differences if this were the case.
Finally, we had no measure of EPA adherence so it was not
possible to establish a dose–response relationship. Further-
more, we did not assess dietary intake of essential fatty
acids (although the dose given was 10 to 20 times the
amount of EPA found in 100 g of tuna).
The MRS analysis used in this study utilizes a library of
complex multipeak metabolite spectra that are matched and
scaled to fit the observed subject spectrum (Provencher,
1993). Although peaks from other metabolites overlap with
the glutathione spectrum, it is possible to detect contribu-
tions from metabolites with complex spectra, such as
glutathione, even when the individual metabolite is not
clearly visible in the spectrum (Pfeuffer et al, 1999a, bQ5 ).
Comparisons of a short-echo single-voxel acquisition
method, as used in this study, with spectral editing
techniques for glutathione measurement showed that the
method used in our study gives comparable measurements
(Oz et al, 2006).
In conclusion, the addition of E-EPA to standard
treatment in early psychosis results in a large increase in
glutathione in both temporal lobes, and to a lesser extent, an
increase in glutamate/glutamine that reaches level of
significance only in the left hippocampus. Negative
symptom improvements correlated with increases in the
concentration of a number of metabolites, in particular
glutathione. We speculate that the tightly coupled increase
in GSH and GLX can be explained via a protective effect of
E-EPA on astrocytes, which promotes antioxidative defense
mechanisms and secures a proper functioning of the
glutamate/glutamine cycle in early psychosis. Our results
provide encouragement to further investigate E-EPA as a
potential neuroprotective agent.
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